Specialist-led weight care is here.Check eligibility
Zelta
All articles
Research summary11 min read

Semaglutide side effects: what to expect, and when to call your doctor

Nausea, constipation, acidity and hair loss on semaglutide: how often they happen, why they peak as the dose rises, and when to call your doctor.

Most side effects of semaglutide affect the gut. In the weight-loss trials of semaglutide 2.4 mg in the US prescribing label, nausea affected 44 % of people against 16 % on a dummy injection (placebo)1. Diarrhoea, vomiting, constipation and stomach pain came next1. An expert consensus and a diabetes leaflet from the UK's National Health Service (NHS) both advise smaller, slower meals and less fatty food2,3. In a pooled analysis of the main trials, almost all of these problems were mild to moderate, and most came during or soon after a dose increase4. Even so, 4.3 % of people stopped treatment because of them4.

Severe, lasting stomach pain needs help straight away; vomiting that stops you keeping fluids down needs help that day2,5.

How common is each side effect?

Nausea is the most common side effect, at 44 % against 16 % on placebo1. Each figure only means something next to the placebo figure, because people on a dummy injection also report nausea and headaches.

Side effects in the weight-loss trials of semaglutide 2.4 mg once a week, against placebo1. Source: the US prescribing label for Wegovy.

Side effect Semaglutide 2.4 mg Placebo
Nausea 44 % 16 %1
Diarrhoea 30 % 16 %1
Vomiting 24 % 6 %1
Constipation 24 % 11 %1
Stomach (abdominal) pain 20 % 10 %1
Headache 14 % 10 %1
Tiredness (fatigue) 11 % 5 %1
Indigestion (dyspepsia) 9 % 3 %1
Dizziness 8 % 4 %1
Burping 7 % under 1 %1
Bloated stomach 7 % 5 %1
Acid reflux 5 % 3 %1
Hair loss 3 % 1 %1

The NHS lists most of the same effects as common, hair loss among them, and adds skin reactions where the injection goes in6. In India, this weight-loss dose is sold as Wegovy, launched on 24 June 2025, and as Poviztra7,8. These rates come from the trials behind the US label, not from a study in India.

Why side effects cluster when the dose goes up

Semaglutide slows how fast the stomach empties after a meal, so you can feel full sooner and for longer than before2. An obesity specialist at the Cleveland Clinic in the US says side effects are often worst in the first three to four weeks, when stomach emptying is slowest9.

For this reason the US label starts the weight-loss injection low and steps the dose up slowly, to lower the risk of digestive side effects1. It starts at 0.25 mg once a week for 4 weeks1. The dose then rises to 0.5 mg, 1 mg and 1.7 mg, each for 4 weeks, and the usual long-term (maintenance) dose is 2.4 mg once a week1. In India, Wegovy comes in a pre-filled pen in five dose strengths7.

Digestive side effects are more likely at the start and soon after each increase, and they usually settle once the maintenance dose is reached3,10. If one step is too hard to cope with, the US label lets the doctor delay the next step by 4 weeks1. Each step and its timing are set out in our semaglutide dose schedule.

Nausea and vomiting

Advice from expert groups and the NHS lines up closely, and most of it is about how much, and how fast, you eat:

  • Eat smaller portions, eat only when you are hungry, and stop when you feel full3.
  • Eat slowly. The brain can take up to 30 minutes after a meal to register a full stomach9.
  • Avoid fried, fatty and greasy food2,11. Pakoras, samosas, puris and rich gravies all count.
  • Do not lie down soon after eating3,11.
  • Do not have a large drink with a meal11. If nausea keeps coming back, drink 30 to 60 minutes before or after meals instead3, and sip water through the day9.
  • Have breakfast, then small meals every 3 to 4 hours with enough fluids; ginger or peppermint tea may also help12.

If these changes do not help, tell your doctor soon rather than waiting it out3. If you keep vomiting and cannot keep fluids down, get medical help that day5.

Constipation and diarrhoea

Constipation lasts longer than the other digestive side effects. In an analysis that combined the main weight-loss trials, half of the people with constipation had it for 47 days or longer3.

Constipation. The medicine makes people feel full, so many drink less water, and that can make constipation more likely3. The usual advice is more water, more fibre and more movement through the day, and a doctor may suggest a stool softener3. Go easy on extra fibre when your stomach already feels bloated or tight after a dose, because it may be too much for the gut at that point9. See a doctor if constipation does not improve, keeps coming back, comes with regular bloating, or you see blood13.

Diarrhoea and dehydration. Avoiding large or fatty meals can help with diarrhoea12. According to the US label, most kidney problems reported with semaglutide happened in people who had become dehydrated after nausea, vomiting or diarrhoea1. The UK medicines regulator advises plenty of fluids, such as water, throughout treatment, and warns that severe dehydration can damage the kidneys badly enough to need hospital care10.

An Indian expert panel advises more than 2 litres a day of water or drinks without sugar14. If your doctor has told you to limit fluids, follow that advice instead. A simple check from the NHS is to drink enough that your urine stays pale15.

Acidity, heartburn and burping

Burping affected 7 % of people on semaglutide 2.4 mg against under 1 % on placebo1. Indigestion affected 9 % against 3 %1. Food stays in the stomach longer on this medicine, so a large meal can bring on nausea and a lot of acid reflux2,9.

For reflux, general NHS advice is to avoid the foods and drinks that set it off16. Finish eating 3 to 4 hours before bed, and skip clothes that are tight around the waist16. An Indian expert panel says eating slowly and avoiding large evening meals can improve tolerance and reduce nausea14. Alcohol can make nausea and reflux worse; the NHS advises avoiding it6,12. Ask your doctor before you add any medicine for acidity.

Tiredness, headache and hair loss

Both tiredness and headache were more common than on placebo, as the table shows1. Hair loss is less frequent, at 3 % against 1 %1, although the NHS still lists it among the common side effects6. A 2026 systematic review found rapid weight loss to be a possible contributor, through a type of shedding called telogen effluvium17. The American Academy of Dermatology, a US body, lists a loss of 20 pounds (about 9 kg) or more among the common triggers of this shedding18. Once the trigger has passed and the body has adjusted, the shedding stops, and hair usually regains its fullness within six to nine months18. If the trigger does not go away, the shedding can continue for a long time18.

Serious side effects: emergencies and urgent signs

Some signs need prompt care. India's government lists severe pancreatitis, kidney injury and bowel obstruction among the complications of GLP-1 medicines19.

Call 112, India's emergency number, at once for:20

  • A serious allergic reaction: a swollen throat or tongue, a raised itchy rash, or difficulty breathing6.
  • Very low blood sugar in someone who is not responding normally, or is unconscious21. Do not give an unconscious person food or drink21.

Get medical help straight away for:

  • Severe stomach pain that does not go away and may spread to the back, with or without vomiting. This can be a sign of an inflamed pancreas (pancreatitis). The US Medication Guide says to stop the medicine and call the doctor right away1.
  • Sudden loss of vision, usually in one eye6.
  • Pain in the upper stomach, yellow skin or eyes, fever, or pale (clay-coloured) stools. These can be signs of gallbladder problems, including gallstones1.
  • Severe constipation, or a gut that seems blocked. Reports collected after approval include ileus (the gut stops moving), intestinal obstruction and severe constipation1.

Contact your doctor the same day for:

  • Vomiting that stops you keeping fluids down, which risks dehydration and kidney harm, or bloody diarrhoea1,5.
  • Changes in your vision, if you have diabetic eye disease6.

Low blood sugar can cause sweating, shaking, a pounding heart or dizziness, and the US label says the risk may be higher with insulin or a sulfonylurea1,6. For a person with diabetes, the NHS says it needs quick treatment, such as a small glass of fruit juice21. Then tell your doctor.

The US label also carries a boxed warning on thyroid tumours. Semaglutide caused thyroid C-cell tumours in rodents, and whether it does so in people is not known1. Medullary thyroid cancer starts in these C cells22. People with a personal or family history of it, or with MEN 2 (multiple endocrine neoplasia type 2), must not use semaglutide1. The US label asks doctors to tell patients the signs to report: a lump in the neck, trouble swallowing, shortness of breath, or hoarseness that does not go away1.

Before an operation or a dental procedure with a general anaesthetic or a sedative, tell the doctor or dentist that you use semaglutide6. For milder side effects that bother you or do not go away, speak to your doctor, and keep taking the medicine unless you are told to stop6. You can also report a suspected side effect yourself to India's Pharmacovigilance Programme (PvPI), whose helpline is 1800 180 3024 on working days23,24.

Semaglutide in India: the same medicine under many names

Semaglutide is sold in India under several brand names, for diabetes and for weight loss. Rybelsus tablets are sold for type 2 diabetes in 3, 7 and 14 mg strengths25, and the GLP-1 tablets guide covers them. Novo Nordisk launched the Ozempic injection here on 12 December 202526. According to Novo Nordisk India in December 2025, Ozempic comes in 0.25 mg, 0.5 mg and 1 mg strengths for type 2 diabetes, and the 2.4 mg weight-loss dose is kept for Wegovy27.

The patent on semaglutide expired in India on 20 March 202628. Generic brands followed that month, including Noveltreat (Sun Pharma), Obeda (Dr Reddy's) and Sundae (Eris)29. CDSCO is India's drug regulator. Most of the generic approvals that we read in its minutes are for type 2 diabetes, and some brands are reported for weight management too30. Our guide to GLP-1 medicines in India lists more brands.

Most of the same side effects can occur with any brand, because the active ingredient is the same. The rates in the table were measured at the 2.4 mg weight-loss dose, and they may be different at the lower doses used for diabetes1,27. Before you start any brand, check these three points:

  1. A prescription. India's government advises getting GLP-1 medicines only on prescription, through regulated channels19. Pharmacy listings show Ozempic and Wegovy as prescription-only (Schedule H) medicines31,32. In March 2026, the government was reported to have warned that generic semaglutide must be sold only with a registered doctor's prescription33. For weight-loss drugs, a health-ministry release names specialists34.
  2. A registered pharmacy. In April 2026, Haryana's drug regulator was reported to have seized more than 260 suspected counterfeit Mounjaro pens35. Mounjaro (tirzepatide) is a different medicine. The NHS warns that some websites sell fake weight-loss medicines, and advises a registered pharmacy36.
  3. Storage in the heat. Pens differ between brands, so follow the leaflet in your own pack. According to PharmEasy, an Indian online pharmacy, Wegovy pens stay in a fridge at 2–8 °C before first use and are never frozen37. It also says never to use a pen that has been frozen, left in a hot car or in direct sun37. For comparison only, the US label allows the Wegovy FlexTouch pen 56 days at 15–30 °C, or in the fridge, after first use1.

Frequently asked questions

Is Ozempic the same as semaglutide? Yes. Ozempic is a brand of semaglutide, sold in India in 0.25 mg, 0.5 mg and 1 mg strengths for type 2 diabetes26,27. It can cause the same kinds of side effect, but the rates on this page come from the 2.4 mg weight-loss dose1.

What happens if I stop semaglutide? Talk to your doctor first, and do not stop suddenly6. For people with type 2 diabetes, stopping could also affect blood sugar6. In the STEP 1 trial extension, people stopped both semaglutide 2.4 mg and the lifestyle programme38. A year later, they had regained, on average, two-thirds of the weight they had lost38.

Is semaglutide right for me? That depends on your health and on the other medicines you take. Some people must not use it at all, as our page on who should not take GLP-1 medicines sets out. Readers comparing it with tirzepatide can see GLP-1 side effects, medicine by medicine. Talk to a Zelta specialist about your own options.

Sources

  1. Wegovy US label (DailyMed, 2026-06-18)
  2. Leeds Community Healthcare NHS Trust, diabetes patient leaflet 'GLP-1 or GIP diabetes treatment' (page dated 2026-04-30)
  3. Gorgojo-Martinez et al., 'Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus', J Clin Med (2022-12-24), PMID 36614945
  4. Wharton et al., 'Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity', Diabetes Obes Metab (2022; online 2021-10-04), pooled STEP 1-3 analysis, PubMed abstract, PMID 34514682; several authors are Novo Nordisk employees
  5. NHS, 'Diarrhoea and vomiting' (page last reviewed 2023-12-21)
  6. NHS medicines guide: semaglutide
  7. Business Today, 2025-06-24
  8. BioSpectrum India, 2025-11-10
  9. Cleveland Clinic Health Essentials, 'How to manage GLP-1 side effects' (2026-09-09)
  10. UK MHRA Drug Safety Update, volume 18 issue 3 (October 2024)
  11. NHS, 'Feeling sick (nausea)' (page last reviewed 2023-11-17)
  12. Joint advisory of the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association and The Obesity Society, 'Nutritional priorities to support GLP-1 therapy for obesity', Obesity Pillars (2025-06-03), PMID 40673264
  13. NHS, 'Constipation' (page last reviewed 2023-10-26)
  14. Joshi et al., 'Nutritional considerations for glucagon-like peptide-based therapies: An Asian Indian consensus recommendation', Obesity Pillars (2026-07-15), PMID 42529748; funded by Abbott Healthcare
  15. NHS, 'Dehydration' (page last reviewed 2026-05-01)
  16. NHS, 'Heartburn and acid reflux' (page last reviewed 2023-11-20)
  17. Gupta et al., 'GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling', Sci Prog (2026-04-17), PubMed abstract, PMID 41998799
  18. American Academy of Dermatology, 'Do you have hair loss or hair shedding?' (no date shown)
  19. PIB backgrounder 'GLP-1 Drugs: Use, Risks, and Regulation', 2026-04-01
  20. Government of Meghalaya, DIPR press release, 2026-05-27
  21. NHS, 'Low blood sugar (hypoglycaemia)' (read 2026-10-21)
  22. NCI Dictionary of Cancer Terms: medullary thyroid cancer (undated, read 2026-10-21)
  23. Indian Pharmacopoeia Commission, PvPI page (undated, read 2026-10-21)
  24. Indian Pharmacopoeia Commission, PvPI FAQ (undated, read 2026-10-21)
  25. PharmEasy, updated 2026-10-01 (pharmacy listing)
  26. The South First, 2025-12-12
  27. Storyboard18, 2025-12-15 (Novo Nordisk India MD to CNBC-TV18)
  28. CareEdge, 2026-03-10
  29. ThePrint 2026-03-21; Outlook Business 2026-03-20; Torrent NSE filing 2026-03-21
  30. CDSCO SEC minutes and press reports
  31. PharmEasy, updated 2026-10-01 (pharmacy listing)
  32. PharmEasy, updated 2026-10-01 (pharmacy listing)
  33. SuperKalam summary of the Indian Express, 2026-03-12
  34. Ministry of Health and Family Welfare press release via PIB, 2026-03-24
  35. Khaleej Times (Reuters), 2026-04-20
  36. NHS medicines guide: tirzepatide
  37. PharmEasy, 'Wegovy: Uses, Dosage and Side Effects' (read 2026-10-21) (pharmacy listing)
  38. PubMed abstract, PMID 35441470

Medical Disclaimer

This article is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. The clinical trial results cited in this article reflect study averages from specific trial populations and may not predict individual outcomes. Drug availability, approved indications, and brand names vary by country and are subject to regulatory decisions by bodies such as the CDSCO in India, the FDA in the United States, and the EMA in Europe. Zelta does not endorse one medication over another. All treatment decisions are made by your prescribing clinician based on your individual health profile.

Ready to begin?

Find out if GLP-1 is right for you.

Take our free 2-minute assessment. A specialist doctor reviews every case.

Take free assessment